Logo image of ZURA

ZURA BIO LTD (ZURA) Stock Price, Quote, News and Overview

NASDAQ:ZURA - Nasdaq - KYG9TY5A1016 - Common Stock - Currency: USD

1.4  -0.04 (-2.78%)

After market: 1.47 +0.07 (+5%)

ZURA Quote, Performance and Key Statistics

ZURA BIO LTD

NASDAQ:ZURA (2/21/2025, 8:00:02 PM)

After market: 1.47 +0.07 (+5%)

1.4

-0.04 (-2.78%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High6.35
52 Week Low1.35
Market Cap91.41M
Shares65.29M
Float46.49M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-27 2025-03-27/bmo
IPO07-16 2021-07-16


ZURA short term performance overview.The bars show the price performance of ZURA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

ZURA long term performance overview.The bars show the price performance of ZURA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of ZURA is 1.4 USD. In the past month the price decreased by -18.6%. In the past year, price decreased by -61.64%.

ZURA BIO LTD / ZURA Daily stock chart

ZURA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About ZURA

Company Profile

ZURA logo image Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies and are Phase II ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Company Info

ZURA BIO LTD

4225 Executive Square, Suite 600

La Jolla CALIFORNIA US

Employees: 15

Company Website: https://zurabio.com/

Investor Relations: https://investors.zurabio.com/

Phone: 18582470520

ZURA BIO LTD / ZURA FAQ

What is the stock price of ZURA BIO LTD today?

The current stock price of ZURA is 1.4 USD. The price decreased by -2.78% in the last trading session.


What is the ticker symbol for ZURA BIO LTD stock?

The exchange symbol of ZURA BIO LTD is ZURA and it is listed on the Nasdaq exchange.


On which exchange is ZURA stock listed?

ZURA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ZURA BIO LTD stock?

14 analysts have analysed ZURA and the average price target is 14.57 USD. This implies a price increase of 940.81% is expected in the next year compared to the current price of 1.4. Check the ZURA BIO LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ZURA BIO LTD worth?

ZURA BIO LTD (ZURA) has a market capitalization of 91.41M USD. This makes ZURA a Micro Cap stock.


How many employees does ZURA BIO LTD have?

ZURA BIO LTD (ZURA) currently has 15 employees.


What are the support and resistance levels for ZURA BIO LTD (ZURA) stock?

ZURA BIO LTD (ZURA) has a resistance level at 1.56. Check the full technical report for a detailed analysis of ZURA support and resistance levels.


Should I buy ZURA BIO LTD (ZURA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ZURA BIO LTD (ZURA) stock pay dividends?

ZURA does not pay a dividend.


When does ZURA BIO LTD (ZURA) report earnings?

ZURA BIO LTD (ZURA) will report earnings on 2025-03-27, before the market open.


What is the Price/Earnings (PE) ratio of ZURA BIO LTD (ZURA)?

ZURA BIO LTD (ZURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.64).


What is the Short Interest ratio of ZURA BIO LTD (ZURA) stock?

The outstanding short interest for ZURA BIO LTD (ZURA) is 10.5% of its float. Check the ownership tab for more information on the ZURA short interest.


ZURA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ZURA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ZURA. ZURA has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZURA Financial Highlights

Over the last trailing twelve months ZURA reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 86.21% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -22.54%
ROE -27.85%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-44.44%
Sales Q2Q%N/A
EPS 1Y (TTM)86.21%
Revenue 1Y (TTM)N/A

ZURA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to ZURA. The Buy consensus is the average rating of analysts ratings from 14 analysts.


Ownership
Inst Owners62.81%
Ins Owners7.96%
Short Float %10.5%
Short Ratio8.78
Analysts
Analysts85.71
Price Target14.57 (940.71%)
EPS Next Y75.07%
Revenue Next YearN/A